Fenobarbital: interakcje

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (etykieta leku Abirateron, Interakcje z innymi lekami)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (etykieta leku Akalabrutynib, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Abuse and misuse of phenobarbital commonly involve concomitant use of other drugs, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes [see Warnings and Precaution (5.3)]. (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etykieta leku Alpelisyb, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (etykieta leku Apiksaban, Interakcje z innymi lekami)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (etykieta leku Apremilast, Ostrzeżenia i środki ostrożności)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…(with or without ritonavir) with carbamazepine is contraindicated due to the risk for loss of virologic response and development of resistance [see Contraindications (4) ]. phenytoin, phenobarbital ↓ atazanavir ↓ phenytoin ↓ phenobarbital Coadministration of REYATAZ (with or without ritonavir) with phenytoin or phenobarbital is contraindicated due to the risk for… (etykieta leku Atazanawir, Interakcje z innymi lekami)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (etykieta leku Azelastyna + flutykazon, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Concomitant administration with oxcarbazepine or phenobarbital is not recommended. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Interakcje z innymi lekami)

Strong CYP3A4 Inducers: Avoid concomitant use. (etykieta leku Bortezomib, Interakcje z innymi lekami)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etykieta leku Bosutynib, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.3)] . (etykieta leku Bupropion, Przeciwwskazania)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (etykieta leku Cetyryzyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (etykieta leku Darunawir, Przeciwwskazania)

Co-administration of PREZCOBIX or PREZCOBIX PED with CYP3A inducers may lead to lower exposures of darunavir and cobicistat and potential loss of efficacy of darunavir and possible resistance. (etykieta leku Darunawir + kobicystat, Przeciwwskazania)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etykieta leku Dazatynib, Interakcje z innymi lekami)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (etykieta leku Deflazakort, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (etykieta leku Difenoksylat + atropina, Przeciwwskazania)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (etykieta leku Diwalproeks (walproinian), Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (etykieta leku Doksorubicyna, Interakcje z innymi lekami)

Central nervous system (CNS) depressants: Concurrent use with alcohol or other CNS depressants is not recommended ( 5.1 ) (etykieta leku Doksylamina + pirydoksyna, Ostrzeżenia i środki ostrożności)

PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] . (etykieta leku Dorawiryna, Przeciwwskazania)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etykieta leku Eleksakaftor + tezakaftor + iwakaftor, Ostrzeżenia i środki ostrożności)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Przeciwwskazania)

…virologic response and possible resistance to COMPLERA or to the class of NNRTIs [see Warnings and Precautions (5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose)… (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Przeciwwskazania)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (etykieta leku Etrawiryna, Interakcje z innymi lekami)

IT IS NOT KNOWN WHETHER CONCOMITANT USE OF OTHER ANTIEPILEPTIC DRUGS AND/OR OTHER DRUGS AFFECT THE INCIDENCE OF HEPATIC FAILURE. (etykieta leku Felbamat, Ostrzeżenie w ramce)

Phenelzine sulfate should not be used in combination with dextromethorphan or with CNS depressants such as alcohol and certain narcotics. (etykieta leku Fenelzyna, Przeciwwskazania)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…spasms in the urinary tract collection system, inactivation of nerve and muscle cells after administration of drugs to relax the muscles (depolarization block after depolarizing muscle relaxants), in case of intoxication due to “irreversibly acting” cholinesterase inhibitors (drugs used to treat dementia), intoxication with phosphoric acid esters or barbiturates. (etykieta leku Fizostygmina, Przeciwwskazania)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (etykieta leku Flibanseryna, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (etykieta leku Fosamprenawir, Przeciwwskazania)

• Respiratory Depression: May occur with NEURONTIN when used with concomitant central nervous system (CNS) depressants, including opioids, or in the setting of underlying respiratory impairment. (etykieta leku Gabapentyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etykieta leku Irynotekan, Interakcje z innymi lekami)

Anticonvulsants Carbamazepine Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etykieta leku Iwabradyna, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made 5,6 . (etykieta leku Izoniazyd, Interakcje z innymi lekami)

• Coadministration with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine. (etykieta leku Kabotegrawir, Przeciwwskazania)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (etykieta leku Kabozantynib, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (etykieta leku Karbinoksamina, Ostrzeżenia i środki ostrożności)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (etykieta leku Klonidyna, Ostrzeżenia i środki ostrożności)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (etykieta leku Kwas walproinowy, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid strong CYP3A4 inducers. (etykieta leku Lapatynib, Interakcje z innymi lekami)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (etykieta leku Larotrektynib, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Concomitant administration of SUNLENCA with oxcarbazepine or phenobarbital is not recommended. (etykieta leku Lenakapawir, Interakcje z innymi lekami)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (etykieta leku Lewocetyryzyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

KALETRA once daily in combination with carbamazepine, phenobarbital, or phenytoin is not recommended. (etykieta leku Lopinawir + rytonawir, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etykieta leku Lorlatynib, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etykieta leku Macytentan, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. (etykieta leku Mifepryston, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etykieta leku Naldemedyna, Interakcje z innymi lekami)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (etykieta leku Nalmefen, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (etykieta leku Naloksegol, Interakcje z innymi lekami)

CYP2B6 Inducers (e.g., ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) may reduce efficacy by reducing bupropion exposure, avoid concomitant use. (etykieta leku Naltrekson + bupropion, Interakcje z innymi lekami)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (etykieta leku Nifedypina, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

…contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (etykieta leku Nirmatrelwir + rytonawir, Przeciwwskazania)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (etykieta leku Noretysteron + etynyloestradiol, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Central Nervous System Depression Xyrem (sodium oxybate) is a CNS depressant. (etykieta leku Oksybat sodu, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (etykieta leku Olopatadyna, Ostrzeżenia i środki ostrożności)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (etykieta leku Olopatadyna + mometazon, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (etykieta leku Palbocyklib, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (etykieta leku Prazykwantel, Przeciwwskazania)

• Respiratory Depression : May occur with LYRICA when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. (etykieta leku Pregabalina, Ostrzeżenia i środki ostrożności)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

SEZABY is contraindicated in patients with: acute porphyrias [see Warnings and Precautions (5.8)], or a history of hypersensitivity reaction to phenobarbital or other barbiturates [see Warnings and Precautions (5.7)] Acute porphyrias (4) (etykieta leku Fenobarbital, Przeciwwskazania)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (etykieta leku Roflumilast, Interakcje z innymi lekami)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (etykieta leku Rolapitant, Interakcje z innymi lekami)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (etykieta leku Romidepsyna, Interakcje z innymi lekami)

Table 2: Drugs That are Contraindicated with EDURANT and EDURANT PED Drug Class Contraindicated Drugs in Class Clinical Comment Anticonvulsants Carbamazepine Oxcarbazepine Phenobarbital Phenytoin Potential for significant decreases in rilpivirine plasma concentrations due to CYP3A enzyme induction, which may result in loss of virologic response. (etykieta leku Rylpiwiryna, Przeciwwskazania)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (etykieta leku Rymegepant, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (etykieta leku Rytlecytynib, Interakcje z innymi lekami)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (etykieta leku Rytonawir, Ostrzeżenie w ramce)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (etykieta leku Rywaroksaban, Ostrzeżenia i środki ostrożności)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ sofosbuvir ↓ velpatasvir ↓ voxilaprevir Coadministration is not recommended. (etykieta leku Sofosbuwir + welpataswir, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etykieta leku Sorafenib, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (etykieta leku Syrolimus, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (etykieta leku Tikagrelor, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (etykieta leku Tiotepa, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (etykieta leku Tolwaptan, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (etykieta leku Trabektedyna, Interakcje z innymi lekami)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS Risks from Concomitant Use with Opioids Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation,… (etykieta leku Fenobarbital, Ostrzeżenie w ramce)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etykieta leku Ubrogepant, Interakcje z innymi lekami)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (etykieta leku Uliprystal, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etykieta leku Upadacytynib, Interakcje z innymi lekami)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (etykieta leku Vepdegestrant, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

CNS depressants: Closely monitor for sedation and respiratory depression. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. (etykieta leku Acetazolamid, Interakcje z innymi lekami)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (etykieta leku Aksytynib, Interakcje z innymi lekami)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etykieta leku Albendazol, Ostrzeżenia i środki ostrożności)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (etykieta leku Allopurynol, Ostrzeżenia i środki ostrożności)

30% increase Phenobarbital (PB) Similar to aminoglutethimide. (etykieta leku Aminofilina, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina + atorwastatyna, Interakcje z innymi lekami)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (etykieta leku Amlodypina + benazepryl, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina + olmesartan, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (etykieta leku Amlodypina + walsartan, Interakcje z innymi lekami)

Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (etykieta leku Amoksapina, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic… (etykieta leku Artykaina + adrenalina, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Beklometazon, Ostrzeżenia i środki ostrożności)

Alcohol, barbiturates or narcotics: Concomitant administration of thiazide diuretics with alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. (etykieta leku Benazepryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (etykieta leku Bexagliflozin, Interakcje z innymi lekami)

Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (etykieta leku Bisoprolol + hydrochlorotiazyd, Środki ostrożności)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (etykieta leku Bromfeniramina + pseudoefedryna + dekstrometorfan, Interakcje z innymi lekami)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid + formoterol, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (etykieta leku Buspiron, Interakcje z innymi lekami)

Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (etykieta leku Cenobamat, Interakcje z innymi lekami)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Chloroprokaina, Środki ostrożności)

Alcohol, Barbiturates, or Narcotics - potentiation of orthostatic hypotension may occur. (etykieta leku Chlorotiazyd, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Cyklezonid, Ostrzeżenia i środki ostrożności)

John’s Wort rifampin oxcarbazepine octreotide phenobarbital orlistat phenytoin sulfinpyrazone terbinafine ticlopidine Bosentan Coadministration of bosentan (250 to 1000 mg every 12 hours based on tolerability) and cyclosporine (300 mg every 12 hours for 2 days then dosing to achieve a C min of 200 to 250 ng/mL) for 7 days in healthy subjects resulted in decreases… (etykieta leku Cyklosporyna, Interakcje z innymi lekami)

CNS Depressants Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents. (etykieta leku Cyproheptadyna, Ostrzeżenia)

The concomitant use of Exjade with potent UGT inducers (e.g., rifampicin, phenytoin, phenobarbital, ritonavir) may result in a decrease in Exjade efficacy due to a possible decrease in deferasirox concentration. (etykieta leku Deferazyroks, Interakcje z innymi lekami)

Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (etykieta leku Dekschlorfeniramina, Ostrzeżenia)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etykieta leku Dekslanzoprazol, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Dezogestrel + etynyloestradiol, Interakcje z innymi lekami)

Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc). (etykieta leku Difenhydramina, Interakcje z innymi lekami)

MOTOFEN ® may potentiate the action of barbiturates, tranquilizers, narcotics, and alcohol. (etykieta leku Difenoksyna + atropina, Interakcje z innymi lekami)

Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics). (etykieta leku Diklofenak, Ostrzeżenia i środki ostrożności)

Exercise caution when prescribing diclofenac sodium/misoprostol with concomitant drugs that are known to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics). (etykieta leku Diklofenak + mizoprostol, Ostrzeżenia i środki ostrożności)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (etykieta leku Dimenhydrynat, Ostrzeżenia)

Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (etykieta leku Doksepina, Ostrzeżenia i środki ostrożności)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (etykieta leku Dokserkalcyferol, Interakcje z innymi lekami)

Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline. (etykieta leku Doksycyklina, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St. (etykieta leku Drospirenon + etynyloestradiol, Interakcje z innymi lekami)

Potential for Other Drugs to Affect Efavirenz Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations [ see Dosage and Administration ( 2.2 ) ]. (etykieta leku Efawirenz, Interakcje z innymi lekami)

Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of EFV resulting in lowered plasma concentrations. (etykieta leku Efawirenz + lamiwudyna + tenofowir, Interakcje z innymi lekami)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etykieta leku Eksemestan, Interakcje z innymi lekami)

Other Agents Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin ↓ TAF Consider alternative anticonvulsant. (etykieta leku Emtrycytabina + tenofowir, Interakcje z innymi lekami)

Hydrochlorothiazide When administered concurrently the following drugs may interact with thiazide diuretics: Alcohol, barbiturates, or narcotics Potentiation of orthostatic hypotension may occur. (etykieta leku Enalapryl + hydrochlorotiazyd, Interakcje z innymi lekami)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (etykieta leku Erlotynib, Interakcje z innymi lekami)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)

Phenobarbital or Primidone: Higher dosage of APTIOM may be necessary. (etykieta leku Eslikarbazepina, Interakcje z innymi lekami)

John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (etykieta leku Estradiol, Interakcje z innymi lekami)

Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive efficacy. (etykieta leku Estradiol + dienogest, Interakcje z innymi lekami)

John's wort ( Hypericum perforatum ) preparations, phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (etykieta leku Estradiol + noretysteron, Interakcje z innymi lekami)

John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. (etykieta leku Estrogeny skoniugowane + bazedoksyfen, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Etonogestrel + etynyloestradiol, Interakcje z innymi lekami)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (etykieta leku Ewerolimus, Interakcje z innymi lekami)

Table 4: Clinically Relevant Interactions Affecting Esomeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Ezomeprazol, Interakcje z innymi lekami)

Anticonvulsants - In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. (etykieta leku Felodypina, Interakcje z innymi lekami)

Intervention: When phenobarbital is added to or withdrawn from treatment, dosage adjustment of FENOPROFEN CALCIUM may be required. (etykieta leku Fenoprofen, Interakcje z innymi lekami)

The concomitant use of alcohol or central nervous system (CNS) depressant drugs with phentermine and topiramate extended-release capsules may potentiate CNS depression or other centrally mediated effects of these agents, such as dizziness, cognitive adverse reactions, drowsiness, light-headedness, impaired coordination, and somnolence. (etykieta leku Fentermina + topiramat, Ostrzeżenia i środki ostrożności)

Additionally, consider alternatives to structurally similar drugs such as carboxamides (e.g., carbamazepine) and hydantoins (e.g., phenytoin) in these same patients. (etykieta leku Fenobarbital, Ostrzeżenia i środki ostrożności)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (etykieta leku Fezoterodyna, Interakcje z innymi lekami)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (etykieta leku Fludrokortyzon, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (etykieta leku Flutykazon, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Flutykazon + salmeterol, Ostrzeżenia i środki ostrożności)

CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ and concomitant drugs. (etykieta leku Fosaprepitant, Ostrzeżenia i środki ostrożności)

John's wort may vary widely based on preparation. theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid 7.2 Drugs Affected by Phenytoin or CEREBYX Table 7 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of CEREBYX). (etykieta leku Fosfenytoina, Interakcje z innymi lekami)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etykieta leku Gefitynib, Interakcje z innymi lekami)

Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (etykieta leku Glikopironium, Interakcje z innymi lekami)

…including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic… (etykieta leku Glimepiryd, Interakcje z innymi lekami)

Barbiturates usually depress griseofulvin activity by decreasing plasma levels and concomitant administration may require a dosage adjustment of the antifungal agent. (etykieta leku Gryzeofulwina, Interakcje z innymi lekami)

Consider the potential for additive sedative effects with CNS depressant drugs. (etykieta leku Guanfacyna, Ostrzeżenia i środki ostrożności)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (etykieta leku Hydrokortyzon, Interakcje z innymi lekami)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (etykieta leku Ifosfamid, Interakcje z innymi lekami)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (etykieta leku Imatynib, Interakcje z innymi lekami)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased, or the antibacterial drug discontinued ( 5.2 ). (etykieta leku Imipenem + cylastatyna, Ostrzeżenia i środki ostrożności)

Imipramine hydrochloride may enhance the CNS depressant effects of alcohol. (etykieta leku Imipramina, Ostrzeżenia)

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. (etykieta leku Iwakaftor, Ostrzeżenia i środki ostrożności)

Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. (etykieta leku Kalcytriol, Interakcje z innymi lekami)

Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin. (etykieta leku Kanagliflozyna, Interakcje z innymi lekami)

Interactions with Hydrochlorothiazide Alcohol, barbiturates, or narcotics − Potentiation of orthostatic hypotension may occur. (etykieta leku Kandesartan + hydrochlorotiazyd, Interakcje z innymi lekami)

Consider alternative drugs to phenobarbital. (etykieta leku Karmustyna, Interakcje z innymi lekami)

Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin acetate for injection is expected to reduce the plasma concentrations of caspofungin acetate for injection. (etykieta leku Kaspofungina, Interakcje z innymi lekami)

Use with CNS Depressants Clemastine has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. (etykieta leku Klemastyna, Ostrzeżenia)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (etykieta leku Klindamycyna, Interakcje z innymi lekami)

Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly ( see CLINICAL PHARMACOLOGY, Interactions ). (etykieta leku Klomipramina, Interakcje z innymi lekami)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (etykieta leku Kolestyramina, Interakcje z innymi lekami)

Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (etykieta leku Kwas acetylosalicylowy + dipirydamol, Interakcje z innymi lekami)

Effects of VYKOURA on Other Drugs Certain Antiepileptic Drugs Increase monitoring for seizure activity in patients taking certain concomitant antiepileptic drugs. (etykieta leku Kwas folinowy (leukoworyna), Interakcje z innymi lekami)

Te leki przeciwpadaczkowe obniżają stężenie folianów, a suplementy kwasu foliowego mogą z kolei obniżać stężenie leku we krwi. (NIH Office of Dietary Supplements, Folate)

Effects of Leucovorin Products on Other Drugs Antiepileptic Drugs Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone and increase the frequency of seizures in susceptible children. (etykieta leku Kwas lewofolinowy, Interakcje z innymi lekami)

Anyone considering prescribing VIMPAT or any other AED must balance this risk with the risk of untreated illness. (etykieta leku Lakozamid, Ostrzeżenia i środki ostrożności)

Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin decrease lamotrigine concentrations by approximately 40%. (etykieta leku Lamotrygina, Interakcje z innymi lekami)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etykieta leku Lanzoprazol, Interakcje z innymi lekami)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ ledipasvir ↓ sofosbuvir Coadministration of ledipasvir and sofosbuvir with carbamazepine, phenytoin, or phenobarbital is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. (etykieta leku Ledipaswir + sofosbuwir, Interakcje z innymi lekami)

Enzyme inducers (e.g., CYP3A4) : May decrease the effectiveness of TYBLUME or increase breakthrough bleeding. (etykieta leku Lewonorgestrel + etynyloestradiol, Interakcje z innymi lekami)

Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Lidokaina + prylokaina, Interakcje z innymi lekami)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (etykieta leku Linagliptyna, Interakcje z innymi lekami)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (etykieta leku Linagliptyna + metformina, Interakcje z innymi lekami)

Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. (etykieta leku Lizynopryl + hydrochlorotiazyd, Interakcje z innymi lekami)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (etykieta leku Lofeksydyna, Ostrzeżenia i środki ostrożności)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (etykieta leku Marawirok, Ostrzeżenia i środki ostrożności)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (etykieta leku Medroksyprogesteron, Ostrzeżenia i środki ostrożności)

Anticonvulsants In patients taking an anticonvulsant (e.g., valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant. (etykieta leku Meflochina, Interakcje z innymi lekami)

• Coadministration of meclizine hydrochloride with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). (etykieta leku Meklozyna, Interakcje z innymi lekami)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (etykieta leku Memantyna + donepezyl, Interakcje z innymi lekami)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Mepiwakaina, Interakcje z innymi lekami)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (etykieta leku Meprobamat, Ostrzeżenia)

Drug Interactions Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, methsuximide may increase the plasma concentrations of phenytoin and phenobarbital). (etykieta leku Mesuksymid, Interakcje z innymi lekami)

Concomitant use of central nervous system (CNS) depressants or drugs associated with EPS may increase this effect (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics). (etykieta leku Metoklopramid, Ostrzeżenia i środki ostrożności)

Alcohol, Barbiturates, And Narcotics The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. (etykieta leku Metolazon, Interakcje z innymi lekami)

Inducers of CYP450 Liver Enzymes The simultaneous administration of LIKMEZ and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (etykieta leku Metronidazol, Interakcje z innymi lekami)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etykieta leku Metyloprednizolon, Interakcje z innymi lekami)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (etykieta leku Metyrozyna, Interakcje z innymi lekami)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (etykieta leku Mirtazapina, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Mometazon, Ostrzeżenia i środki ostrożności)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (etykieta leku Nalokson, Ostrzeżenia i środki ostrożności)

Table 4: Clinically Significant Interactions with Esomeprazole Magnesium - Affecting Co-Administered Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact : Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Naproksen + ezomeprazol, Interakcje z innymi lekami)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (etykieta leku Newirapina, Interakcje z innymi lekami)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (etykieta leku Nimodypina, Ostrzeżenia i środki ostrożności)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (etykieta leku Nintedanib, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Norelgestromin + etynyloestradiol, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Noretysteron, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Norgestrel + etynyloestradiol, Interakcje z innymi lekami)

Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. (etykieta leku Norgestymat + etynyloestradiol, Interakcje z innymi lekami)

Carbamazepine, Phenytoin, and Phenobarbital: Decreased plasma levels of MHD (the active metabolite). (etykieta leku Okskarbazepina, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Olmesartan + amlodypina + hydrochlorotiazyd, Interakcje z innymi lekami)

Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Omeprazol, Interakcje z innymi lekami)

Table 6: Clinically Relevant Interactions Affecting Omeprazole when Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Omeprazol + wodorowęglan sodu, Interakcje z innymi lekami)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (etykieta leku Orlistat, Ostrzeżenia i środki ostrożności)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when FYCOMPA is used with other drugs with sedative properties because of potential additive effects. (etykieta leku Perampanel, Ostrzeżenia i środki ostrożności)

…including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic… (etykieta leku Pioglitazon + glimepiryd, Interakcje z innymi lekami)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etykieta leku Prednizolon, Interakcje z innymi lekami)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etykieta leku Prednizon, Interakcje z innymi lekami)

Protriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. (etykieta leku Protryptylina, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing… (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (etykieta leku Repaglinid, Interakcje z innymi lekami)

Reduced Rocuronium Bromide Injection activity possible : Anticonvulsants. (etykieta leku Rokuronium, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving… (etykieta leku Ropiwakaina, Interakcje z innymi lekami)

Table 6: Summary of drug-drug interactions of BANZEL with other antiepileptic drugs AED Co-administered Influence of Rufinamide on AED concentration a) Influence of AED on Rufinamide concentration Carbamazepine Decrease by 7 to 13% b) Decrease by 19 to 26% Dependent on dose of carbamazepine Lamotrigine Decrease by 7 to 13% b) No Effect Phenobarbital Increase… (etykieta leku Rufinamid, Interakcje z innymi lekami)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (etykieta leku Ruksolitynib, Interakcje z innymi lekami)

Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. (etykieta leku Ryfabutyna, Interakcje z innymi lekami)

…Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine Decrease exposure Quinidine Decrease exposure… (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…Disopyramide, mexiletine, quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. (etykieta leku Sapropteryna, Interakcje z innymi lekami)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (etykieta leku Selegilina, Interakcje z innymi lekami)

Weigh this potential risk against the benefits before prescribing TRANSDERM SCŌP to patients with a history of seizures, including those receiving anti-epileptic medication or who have risk factors that can lower the seizure threshold. (etykieta leku Skopolamina, Ostrzeżenia i środki ostrożności)

Alcohol, barbiturates, or narcotics: Potentiation of orthostatic hypotension may occur. (etykieta leku Spironolakton + hydrochlorotiazyd, Interakcje z innymi lekami)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etykieta leku Sunitynib, Interakcje z innymi lekami)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (etykieta leku Tadalafil, Interakcje z innymi lekami)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (etykieta leku Telmisartan + amlodypina, Interakcje z innymi lekami)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (etykieta leku Temsyrolimus, Ostrzeżenia i środki ostrożności)

30% increase Phenobarbital (PB) Similar to aminoglutethimide. (etykieta leku Teofilina, Interakcje z innymi lekami)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (etykieta leku Terbinafina, Interakcje z innymi lekami)

Use of tiagabine HCl without enzyme-inducing antiepileptic drugs results in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION ). (etykieta leku Tiagabina, Ostrzeżenia)

…exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ… (etykieta leku Tofacytynib, Interakcje z innymi lekami)

Because of the potential of topiramate to cause CNS depression, as well as other cognitive and/or neuropsychiatric adverse reactions, topiramate extended-release capsules should be used with extreme caution if used in combination with alcohol and other CNS depressants. (etykieta leku Topiramat, Interakcje z innymi lekami)

Excessive reduction of blood glucose (additive effect) f CNS depressant agents (including opioids, alcohol, sedatives, hypnotics) Use with caution d Increased CNS depression Dietary supplements containing sympathomimetics Contraindicated a Antidepressants including but not limited to: Other MAOIs (e.g., linezolid, intravenous methylene blue, selective MAOIs)… (etykieta leku Tranylcypromina, Interakcje z innymi lekami)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (etykieta leku Treprostynil, Ostrzeżenia i środki ostrożności)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etykieta leku Triamcynolon, Interakcje z innymi lekami)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (etykieta leku Triheksyfenidyl, Interakcje z innymi lekami)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (etykieta leku Trimetobenzamid, Ostrzeżenia i środki ostrożności)

Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed ( 7.1, 7.2 ) (etykieta leku Tynidazol, Interakcje z innymi lekami)

…etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral… (etykieta leku Warfaryna, Interakcje z innymi lekami)

Thiopental Reconstituted vecuronium, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions such as thiopental) in the same syringe or administered simultaneously during intravenous infusion through the same needle or through the same intravenous line (see DOSAGE AND ADMINISTRATION -COMPATIBILITY ). (etykieta leku Wekuronium, Środki ostrożności)

Phenobarbital Phenobarbital therapy may increase verapamil clearance. (etykieta leku Werapamil, Interakcje z innymi lekami)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (etykieta leku Wilazodon, Interakcje z innymi lekami)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etykieta leku Winkrystyna, Interakcje z innymi lekami)

Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Interakcje z innymi lekami)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects. (etykieta leku Zonisamid, Ostrzeżenia i środki ostrożności)

Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. (etykieta leku Afatynib, Interakcje z innymi lekami)

Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (etykieta leku Atrakurium, Ostrzeżenia)

Anticonvulsant therapy can be given if clinically indicated. (etykieta leku Cefaleksyna, Ostrzeżenia i środki ostrożności)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (etykieta leku Cefazolina, Ostrzeżenia i środki ostrożności)

…Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). (etykieta leku Cydofowir, Interakcje z innymi lekami)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

A similar association, though less marked, has been suggested for barbiturates, phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin, and tetracyclines. (etykieta leku Dioctan etynodiolu + etynyloestradiol, Interakcje z innymi lekami)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (etykieta leku Docetaksel, Interakcje z innymi lekami)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (etykieta leku Doksapram, Ostrzeżenia)

Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. b Oxcarbazepine Phenytoin Phenobarbital St. (etykieta leku Dolutegrawir, Interakcje z innymi lekami)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etykieta leku Epoetyna alfa, Ostrzeżenia i środki ostrożności)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (etykieta leku Erybulina, Interakcje z innymi lekami)

Data are more extensive with respect to phenytoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs. (etykieta leku Etosuksymid, Ostrzeżenia)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (etykieta leku Fenylomaślan glicerolu, Interakcje z innymi lekami)

Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine). (etykieta leku Ketorolak, Interakcje z innymi lekami)

Other Antiepileptic Drugs Potential drug interactions between levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. (etykieta leku Lewetyracetam, Interakcje z innymi lekami)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (etykieta leku Meksyletyna, Interakcje z innymi lekami)

Anticonvulsants, psychotropic, hormone preparations, corticosteroids, antithyroid agents, cyproheptadine: may affect the results of the metyrapone test. (etykieta leku Metyrapon, Interakcje z innymi lekami)

…glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however), and quinidine; and (6) analgesics, antipyretics… (etykieta leku Prazosyna, Interakcje z innymi lekami)

The impact of other inducers of drug metabolizing enzymes, such as phenytoin and phenobarbital, on UGT1A1 is unknown. (etykieta leku Raltegrawir, Interakcje z innymi lekami)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (etykieta leku Riocyguat, Interakcje z innymi lekami)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Ryfaksymina, Interakcje z innymi lekami)

These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (etykieta leku Tesamorelina, Interakcje z innymi lekami)

Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (etykieta leku Losartan, Interakcje z innymi lekami)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Montelukast, Interakcje z innymi lekami)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (etykieta leku Mykafungina, Interakcje z innymi lekami)